Ophir Energy Plc

Ophir Energy and Coro shares rise but Medco’s takeover intact with improved offer

The Coro approach was described by Ophir as “unsolicited and highly preliminary”, meanwhile, Medco upped the ante to 57.5p, from 55p

oil and gas operations
Coro won't proceed with its envisaged debt-backed, part cash and part equity approach

Ophir Energy Plc (LON:OPHR) shares rose by a little over 2% in Thursday’s early deals to account for a new and improved recommended takeover offer from Indonesia’s Medco Energi.

Medco will now pay shareholders 57.5p per share, which takes the acquisition value to £408.4mln.

It comes amid a surprise and somewhat unlikely move from AIM-quoted small-cap Coro Energy PLC (LON:CORO) which had been exploring a debt-backed approach to potentially gazump the Indonesia buyer.

Coro has now, however, stated that it no longer has an intention to bid for Ophir.

Ophir shares this morning trade at 57.12p each.

READ: Sound Energy says it is “financially well positioned” for 2019

Nevertheless, ambitious Coro also saw its shares in positive territory in Thursday’s deals.

With investors presumably impressed with management’s gumption Coro advanced 6.8% to trade at 2.04p, which values the AIM-quoted firm at £14.65mln.

The Coro approach was described by Ophir as “unsolicited and highly preliminary”, and, noted that a potential offer would’ve seen shareholders receive 40p per share in cash and equity in the enlarged Coro entity (Ophir holders would’ve owned 85-95% of the group).

In September 2018, Coro made its first acquisition in Indonesia paying US$12mln for a 42.5% stake in the Lengo gas field located offshore East Java, Indonesia. It followed an earlier deal to acquire Sound Energy’s Italian interests,

At that time, Coro chief executive James Menzies described Lengo as being “the right scale and in the right address”.

Quick facts: Ophir Energy Plc

Price: £0.00

Market: LSE
Market Cap: £0.00

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

15 hours, 17 minutes ago

2 min read